Fund Details
Overview
Investment portfolio
13rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Laigo Bio | Mar 2026Participated | $19 MSeed | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Laigo Bio | Dec 2025Led | $13 MSeed | |
Avidicure | Apr 2025Participated | $50 MSeed | |
Sirius Medical | Feb 2025Participated | $12 MOther Equity | |
Citryll | Dec 2024Participated | $99 MSeries B | |
Flindr Therapeutics | Apr 2024Participated | $21 MSeries A | |
Sirius Medical | Mar 2023Participated | $13 MSeries B | |
Cleara Biotech | Sep 2022Participated | $3 MSeed | |
CLEARA | Sep 2022Participated | $3 MSeed | |
TargED Biopharmaceuticals | Feb 2022Participated | $44 MSeries A | |
Sirius Medical | Jul 2020Participated | $5 MSeries A | |
Laigo Bio | Mar 2026Participated | $19 MSeed | |
TargED Biopharmaceuticals | Dec 2025Participated | $25 MSeries A | |
Laigo Bio | Dec 2025Led | $13 MSeed | |
Avidicure | Apr 2025Participated | $50 MSeed | |
Sirius Medical | Feb 2025Participated | $12 MOther Equity | |
Citryll | Dec 2024Participated | $99 MSeries B | |
Flindr Therapeutics | Apr 2024Participated | $21 MSeries A | |
Sirius Medical | Mar 2023Participated | $13 MSeries B | |
Cleara Biotech | Sep 2022Participated | $3 MSeed | |
CLEARA | Sep 2022Participated | $3 MSeed | |
TargED Biopharmaceuticals | Feb 2022Participated | $44 MSeries A | |
Sirius Medical | Jul 2020Participated | $5 MSeries A |
13 Items
13
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 4 |
| Series A | 0 | 4 |
| Series B | 0 | 2 |
| Other Equity | 0 | 2 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 1 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 0 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 1 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 2 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 1 |
| Jan '25 | 0 |
| Feb '25 | 1 |
| Mar '25 | 0 |
| Apr '25 | 1 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 2 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 1 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 12 |
| Space & Frontier Tech | 2 |
| Data, Analytics & IT | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 2 |
| $5M-$10M | 1 |
| $10M-$25M | 6 |
| $25M-$50M | 2 |
| $50M-$100M | 2 |
| $100M-$250M | 0 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 12 |
| United States | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| BOM | 7 |
| ROM Utrecht Region | 4 |
| BioGeneration Ventures | 3 |
| Holland Capital | 3 |
| Kurma Partners | 3 |
| Oncode Oncology Bridge Fund | 3 |
| Andera Partners | 2 |
| Angelini Ventures | 2 |
| Apollo Health Ventures | 2 |
| ArgoBio | 2 |
| Cancer Research Horizons | 2 |
| Eurazeo | 2 |
| Fund+ | 2 |
| Hadean Ventures | 2 |
| INKEF Capital | 2 |
| Johnson & Johnson Innovation | 2 |
| Longevity Tech Fund | 2 |
| Sunstone Life Science Ventures | 2 |
| Team Holmium | 2 |
| V-Bio Ventures | 2 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 1 | 8% |
| Participating | 12 | 92% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 1 | 100% |
Team
Han de Groot
Founder and CEO
Mariette van der Velden
Managing Partner